SoloPak Obtains Rights to Ganite

A 6-year analysis of the phase 3 STELLAR trial did not find any significant differences between total neoadjuvant treatment and concurrent chemoradiation in rectal cancer.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Experts highlight research at the 2025 ASCO Annual Meeting that may move the needle in gynecologic cancers, hematologic malignancies, and other fields.

Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.

Clinical data from a phase 1 trial evaluating EBC-129 in solid tumors will be presented at the 2025 American Society of Clinical Society Annual Meeting.

Select adverse effects examined during the initial 24 weeks of treatment occurred at a rare or occasional frequency and mild-to-moderate severity.